JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

Machine Learning Models Predict Early Postoperative Relapse in Pancreatic Cancer
Received Date : 06 May 2021
Accepted Date : 16 Aug 2021
Available Online : 07 Sep 2021
Doi: 10.37047/jos.2021-84326 - Article's Language: EN
J Oncol Sci. 2021;7(3):115-24
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Objective: A risk stratification system for tailoring treatment selection is absent for patients with pancreatic ductal adenocarcinoma (PDAC). Machine learning models can outperform traditional survival models in predicting outcomes and guiding treatment. Therefore, the current study aimed to test the performance of machine learning models in predicting disease-free survival (DFS) and overall survival (OS) in operated PDAC cases. Material and Methods: The demographic, clinical, histopathological, radiologic, and laboratory data for the resected PDAC samples were retrospectively reviewed. Univariate and multivariate conventional survival analyses were conducted for the 6- month DFS and 12-month OS. Two machine learning methods were adopted: a machine learning model, DeepHit, and a gradient boosting decision tree model, LightGBM (Light Gradient Boosting Machine). The performance of these models was compared using the area under the receiver operator characteristic curves (AUROC). Results: For the study, 121 PDAC cases that underwent resection surgery with curative intent were included. The median OS of the study population was 21.9 (11.5-44.4) months, and the median DFS was 11.8 (6-25.6) months. The constructed deep learning model AUROC values were as follows: Relapse at 6 months 0.58 (±0.177) and 0.73 (±0.098); survival over 12 months 0.56 (±0.14) and 0.78 (±0.078); survival over 24 months 0.53 (±0.13), and 0.63 (±0.083). Conclusion: Machine learning models performed similarly to the Cox regression-based dichotomous models. However, further validation of the model in a different and larger dataset is required.
KAYNAKLAR
  1. Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242): 2008-2020. [Crossref]  [PubMed] 
  2. Oba A, Croce C, Hosokawa P, et al. Prognosis based definition of resectability in pancreatic cancer: A road map to new guidelines. Ann Surg. 2020. [Crossref]  [PubMed] 
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7-30. [Crossref]  [PubMed] 
  4. Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol. 2015;21(11):3157-3165. [Crossref]  [PubMed]  [PMC] 
  5. Herreros-Villanueva M, Bujanda L. Non-invasive biomarkers in pancreatic cancer diagnosis: What we need versus what we have. Ann Transl Med. 2016;4(7):134. [Crossref]  [PubMed]  [PMC] 
  6. Regel I, Mayerle J, Mahajan UM. Current strategies and future perspectives for precision medicine in pancreatic cancer. Cancers (Basel). 2020;12(4):1024. [Crossref]  [PubMed]  [PMC] 
  7. Klaiber U, Schnaidt ES, Hinz U, et al. Prognostic factors of survival after neoadjuvant treatment and resection for initially unresectable pancreatic cancer. Ann Surg. 2021;273(1):154-162. [Crossref]  [PubMed] 
  8. Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2014;13:8-17. [Crossref]  [PubMed]  [PMC] 
  9. Ansari D, Nilsson J, Andersson R, Regnér S, Tingstedt B, Andersson B. Artificial neural networks predict survival from pancreatic cancer after radical surgery. Am J Surg. 2013;205(1): 1-7. [Crossref]  [PubMed] 
  10. Ke G, Meng Q, Finley T, et al. Lightgbm: A highly efficient gradient boosting decision tree. Advances in Neural Information Processing Systems. 2017;30:3146-3154. [Link] 
  11. Chen T, Guestrin C. Xgboost: A scalable tree boosting system. Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining. 2016;785-794. [Crossref] 
  12. Shen GQ, Aleassa EM, Walsh RM, Morris-Stiff G. Next-generation sequencing in pancreatic cancer. Pancreas. 2019;48(6):739-748. [Crossref]  [PubMed] 
  13. Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: A retrospective analysis of the know your tumor registry trial. Lancet Oncol. 2020;21(4):508-518. Erratum in: Lancet Oncol. 2020;21(4):e182. [Crossref]  [PubMed]  [PMC] 
  14. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7): 1766- 1773. [Crossref]  [PubMed] 
  15. Chen X, Oshima K, Schott D, et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. PLoS One. 2017;12(6): e0178961. [Crossref]  [PubMed]  [PMC] 
  16. Yokoyama S, Hamada T, Higashi M, et al. Predicted prognosis of patients with pancreatic cancer by machine learning. Clin Cancer Res. 2020;26(10):2411-2421. [Crossref]  [PubMed] 
  17. Bradley A, van der Meer R, McKay C. Personalized pancreatic cancer management: A systematic review of how machine learning is supporting decision-making. Pancreas. 2019; 48(5): 598-604. [Crossref]  [PubMed] 
  18. Iwatate Y, Hoshino I, Yokota H, et al. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. Br J Cancer. 2020; 123(8):1253-1261. [Crossref]  [PubMed]  [PMC] 
  19. Sala Elarre P, Oyaga-Iriarte E, Yu KH, et al. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse. Cancers (Basel). 2019;11(5):606. [Crossref]  [PubMed]  [PMC] 
  20. Dalal V, Carmicheal J, Dhaliwal A, Jain M, Kaur S, Batra SK. Radiomics in stratification of pancreatic cystic lesions: Machine learning in action. Cancer Lett. 2020;469:228-237. [Crossref]  [PubMed]  [PMC] 
  21. De Dosso S, Siebenhüner AR, Winder T, et al. Treatment landscape of metastatic pancreatic cancer. Cancer Treat Rev. 2021;96:102180. [Crossref]  [PubMed] 
  22. Zhang Z, Song J, Xie C, Pan J, Lu W, Liu M. Pancreatic cancer: Recent progress of drugs in clinical trials. AAPS J. 2021;23(2):29. [Crossref]  [PubMed] 
  23. Guo M, Luo G, Liu C, et al. The prognostic and predictive role of epidermal growth factor receptor in surgical resected pancreatic cancer. Int J Mol Sci. 2016;17(7):1090. [Crossref]  [PubMed]  [PMC] 
  24. Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: Better prediction of outcome. Ann Surg. 2011;254(2):311-9. [Crossref]  [PubMed] 
  25. Dell'Aquila E, Fulgenzi CAM, Minelli A, et al. Prognostic and predictive factors in pancreatic cancer. Oncotarget. 2020;11(10):924-941. [Crossref]  [PubMed]  [PMC] 
  26. Binder A, Bockmayr M, Hägele M, et al. Morphological and molecular breast cancer profiling through explainable machine learning. Nature Machine Intelligence. 2021;3:355-366. [Crossref] 
  27. Xie Y, Meng WY, Li RZ, et al. Early lung cancer diagnostic biomarker discovery by machine learning methods. Transl Oncol. 2021; 14(1):100907. [Crossref]  [PubMed]  [PMC] 
  28. Chiu PK, Shen X, Wang G, et al. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study. Prostate Cancer Prostatic Dis. 2021. [Crossref]  [PubMed] 
  29. Reel PS, Reel S, Pearson E, Trucco E, Jefferson E. Using machine learning approaches for multi-omics data analysis: A review. Biotechnol Adv. 2021;49:107739. [Crossref]  [PubMed] 
  30. Salem H, Soria D, Lund JN, Awwad A. A systematic review of the applications of Expert Systems (ES) and machine learning (ML) in clinical urology. BMC Medical Informatics and Decision Making. 2021;21:1-36. [Crossref]  [PubMed]  [PMC] 
  31. Huang S, Yang J, Fong S, Zhao Q. Artificial intelligence in cancer diagnosis and prognosis: Opportunities and challenges. Cancer Lett. 2020;471:61-71. [Crossref]  [PubMed]